Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United ...

(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear ...

In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most ...

Minnesota clinics are starting to receive free or low-cost insulin from Eli Lilly and Sanofi. This comes after the Minnesota ...

In a report released today, Carter Gould from Barclays maintained a Hold rating on Amgen (AMGN – Research Report), with a price target of ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Eli Lilly and Co. wants a federal court to uphold a simple math equation: 41 is greater than 40. The Indianapolis-based drugmaker filed a lawsuit in federal court this month, challenging the U.S. Food ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...